Mechanisms of action of endocrine treatment in breast cancer

Crit Rev Oncol Hematol. 1995 Nov;21(1-3):158-93. doi: 10.1016/1040-8428(94)00172-3.

Abstract

Endocrine treatment plays an important role in the therapy of breast cancer. While the basic mechanisms are understood, additional mechanisms may be of importance to their action and they may also contribute to the mechanism(s) of acquired resistance. Currently, several novel drugs are entering into clinical trials. Observations of the absence or presence of cross resistance to novel 'pure' steroidal antiestrogens and the non-steroidal tamoxifen may add important information to our understanding of the mechanisms of action of both classes of drugs. Similarly, exploration of different aromatase inhibitors in sequence or concert, as well as the combining of different endocrine treatment options may be warranted. Additionally, alterations in different biochemical parameters such as growth factors should not only be carefully explored in relation to treatment options but should also be followed during the course of treatment to asess alterations over time and in relation to the development of drug resistance.

Publication types

  • Review

MeSH terms

  • Adrenal Cortex / drug effects
  • Adrenal Cortex / physiopathology
  • Adult
  • Aged
  • Animals
  • Antineoplastic Agents, Hormonal / classification
  • Antineoplastic Agents, Hormonal / pharmacology*
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Aromatase Inhibitors
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / genetics
  • Breast Neoplasms / physiopathology
  • Breast Neoplasms / therapy
  • Chemotherapy, Adjuvant
  • Combined Modality Therapy
  • Drug Resistance, Multiple
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Estrogen Antagonists / adverse effects
  • Estrogen Antagonists / pharmacology
  • Estrogen Antagonists / therapeutic use
  • Estrogens / blood
  • Estrogens / physiology
  • Female
  • Gene Expression Regulation, Neoplastic / drug effects
  • Gonadotropin-Releasing Hormone / agonists
  • Humans
  • Insulin-Like Growth Factor I / antagonists & inhibitors
  • Insulin-Like Growth Factor I / physiology
  • Mammary Neoplasms, Experimental / drug therapy
  • Mammary Neoplasms, Experimental / physiopathology
  • Menopause
  • Mice
  • Middle Aged
  • Neoplasm Proteins / antagonists & inhibitors
  • Neoplasms, Hormone-Dependent / drug therapy
  • Neoplasms, Hormone-Dependent / genetics
  • Neoplasms, Hormone-Dependent / physiopathology
  • Neoplasms, Hormone-Dependent / therapy
  • Progesterone / antagonists & inhibitors
  • Progesterone / physiology
  • Progestins / antagonists & inhibitors
  • Progestins / pharmacology
  • Progestins / therapeutic use
  • Receptors, Estrogen / drug effects
  • Receptors, Estrogen / physiology
  • Signal Transduction / drug effects
  • Steroids / metabolism
  • Tamoxifen / adverse effects
  • Tamoxifen / pharmacology
  • Tamoxifen / therapeutic use
  • Tumor Cells, Cultured / drug effects

Substances

  • Antineoplastic Agents, Hormonal
  • Aromatase Inhibitors
  • Enzyme Inhibitors
  • Estrogen Antagonists
  • Estrogens
  • Neoplasm Proteins
  • Progestins
  • Receptors, Estrogen
  • Steroids
  • Tamoxifen
  • Gonadotropin-Releasing Hormone
  • Progesterone
  • Insulin-Like Growth Factor I